1,598 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Perpetual Ltd

Perpetual Ltd lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 66.4% in the 3rd quarter, Holdings Channel.com reports. The firm owned 809 shares of the biopharmaceutical company’s stock after selling 1,598 shares during the quarter. Perpetual Ltd’s holdings in Regeneron Pharmaceuticals were worth $613,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Woodstock Corp grew its position in Regeneron Pharmaceuticals by 0.8% in the third quarter. Woodstock Corp now owns 20,684 shares of the biopharmaceutical company’s stock worth $15,684,000 after acquiring an additional 166 shares in the last quarter. Armstrong Advisory Group Inc. raised its position in Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 28 shares during the period. Sound Income Strategies LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $446,000. Riversedge Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 96.9% in the 3rd quarter. Riversedge Advisors LLC now owns 768 shares of the biopharmaceutical company’s stock valued at $582,000 after purchasing an additional 378 shares during the last quarter. Finally, Wedmont Private Capital lifted its stake in shares of Regeneron Pharmaceuticals by 6.9% in the 3rd quarter. Wedmont Private Capital now owns 1,400 shares of the biopharmaceutical company’s stock valued at $1,035,000 after purchasing an additional 90 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 3.4%

Shares of NASDAQ:REGN opened at $778.36 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $564.00 and a 1 year high of $859.34. The business has a 50 day simple moving average of $791.11 and a two-hundred day simple moving average of $720.89. The firm has a market capitalization of $80.14 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 1.30 and a beta of 0.16. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the prior year, the firm posted $12.81 earnings per share. The company’s quarterly revenue was up 16.7% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.93 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. Citigroup lifted their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a report on Tuesday, July 7th. Sanford C. Bernstein raised their price target on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a research report on Friday, August 14th. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Finally, BMO Capital Markets lifted their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $834.24.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president owned 13,134 shares in the company, valued at $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,946 shares of company stock worth $3,302,458 in the last quarter. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.